Table 1. Clinical characteristics of lung cancer patients in the retrospective [Clinical Lung Cancer Genome Project (CLCGP)] and prospective (NGM) data sets.

UICC, Union Internationale Contre le Cancer.

Retrospective CLCGPProspective NGM
Total n12553863
Age at diagnosisn12253019
Median (range)65 (18–94)67 (28–96)
Sex, n (%)Female419 (33.5)1397 (37.2)
Male831 (66.5)2354 (62.8)
Unknown5112
Histology (WHO 2004), n (%)Adenocarcinoma537 (44.5)2250 (62.7)
Carcinoid71 (6)3 (0.08)
Large cell carcinoma*129 (10.7)54 (1.5)
Small cell carcinoma65 (5.4)265 (7.4)
Squamous cell carcinoma403 (33.4)1018 (28.3)
Other/unknown50273
Stage (UICC), n (%)IA305 (25.4)105 (10.4)
IB316 (26.3)72 (7.1)
IIA33 (2.8)56 (5.5)
IIB190 (15.8)49 (4.8)
IIIA195 (16.2)131 (13.0)
IIIB89 (7.4)115 (11.4)
IV74 (6.1)479 (47.5)
Unknown532856
Survival, median no. of monthsI152Not reached
II6649
III3428
IV189.5
Unknown5811.6
Smoking history, n (%)Current/former896 (86)102 (89)
Never147 (14)13 (11)
Unknown2123748

*Including LCNEC.

†Median follow-up time for stage II patients was 16.3 months. Because of short median follow-up time for stage II patients, accuracy of median overall survival in this stage was low (fig. S19).